<DOC>
	<DOCNO>NCT01666132</DOCNO>
	<brief_summary>Intramyocardial , NOGA guide injection bone marrow derive mononuclear cell patient chronic ischemic heart disease LVEF &lt; 40 % . The primary objective determine whether administration cell improve recovery leave ventricular function . Secondary objective find clinical paraclinical parameter predict potential benefit treatment ( base MRI characteristic size , transmurality myocardial infarction peri-lesional ischemia ) . In first part study 10 patient treat without control group . This phase serve feasibility safety part study .</brief_summary>
	<brief_title>METHOD - Bone Marrow Derived Mononuclear Cells Chronic Ischemic Disease</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>Chronic cardiac ischemic disease least 4 month one ore myocardial infarction stable phase disease without option revascularization LVEF echocardiography ≤ 40 % Significant regional LV wall motion dysfunction infarct related territory Symptoms NYHA IIIV CCS IIIII ( least class III accord one two classification ) Patient agree comply followup evaluation Age &gt; 18 year old Patient inform nature clinical trial agree provision provide write informed consent Abnormal regional wall motion outside infarct region Need revascularization non infarctrelated coronary within 6 month Patient moderate severe aortic valve disease , aortic mitral prosthetic valve Patient significant mitral valve insufficiency ( Effective Regurgitant office ERO &gt; 0.2 cm2 possibility mitral valve surgery Left ventricular thrombus echocardiography LVaneurysma plan surgical aneurysmectomy LVwall thickness &lt; 5mm target territory Congenital heart disorder hemodynamic relevance Known active infection chronic infection HIV , HBV HCV Chronic inflammatory disease Serious concomitant disease life expectancy le one year Follow impossible ( fixed abode , etc ) Contraindication cardiac MRI ( i.e . pace maker , neurostimulator , claustrophobia ) Severe renal failure ( creatinine &gt; 250 mmol/l ) Relevant liver disease ( GOT &gt; 2x norm spontaneous INR &gt; 1,5 ) Anemia ( Hb &lt; 8.5 mg/dl ) , Thrombocytopenia ( &lt; 100.000/µl ) Women child bear potential pregnancy Participation clinical trial last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>LVEF &lt; 40 %</keyword>
</DOC>